Arcadia Biosciences (NASDAQ:RKDA) Issues Quarterly Earnings Results

Arcadia Biosciences (NASDAQ:RKDA) announced its quarterly earnings results on Thursday. The basic materials company reported ($2.09) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($1.53), FiscalAI reports. The company had revenue of $1.44 million for the quarter, compared to analyst estimates of $1.90 million. Arcadia Biosciences had a negative return on equity of 113.73% and a negative net margin of 195.94%.

Arcadia Biosciences Trading Down 18.6%

Shares of Arcadia Biosciences stock traded down $0.13 during trading hours on Thursday, reaching $0.57. The stock had a trading volume of 691,056 shares, compared to its average volume of 123,671. Arcadia Biosciences has a twelve month low of $0.50 and a twelve month high of $6.71. The firm has a market capitalization of $1.37 million, a PE ratio of -0.10 and a beta of 0.56. The stock’s 50 day moving average is $0.73 and its 200 day moving average is $1.21.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut Arcadia Biosciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 25th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc, founded in 2002 and headquartered in Davis, California, is an agricultural biotechnology company dedicated to developing crops and food ingredients that promote health and sustainability. By harnessing advanced genomics and precision?breeding technologies, Arcadia creates proprietary trait platforms designed to enhance crop performance, nutritional value, and resilience to environmental stressors. The company’s scientific expertise focuses on non-transgenic approaches, enabling the delivery of novel traits without introducing foreign DNA.

Arcadia’s operations span two main segments: Crop Traits and Food Ingredients.